Dr. Kara Marie Cavuoto, MD

Dr. Cavuoto practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Cavuoto's NPI, 1457500266, was assigned on September 17, 2008. Dr. Cavuoto graduated from University of Miami, Miller School of Medicine in 2007. Dr. Cavuoto holds Florida license ME109152.

Dr. Cavuoto's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Cavuoto's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Cavuoto is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Cavuoto to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cavuoto practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Cavuoto's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Cavuoto is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Cavuoto is licensed in Florida.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eyelid inflammation, glaucoma, vision problems and vitreous eye degeneration among the conditions Dr. Cavuoto treats.

CMS data shows 113 Medicare services from Dr. Cavuoto across 3 procedure codes in 2024, for 127 Medicare patients. Medicare paid $6,425 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 127 Medicare patients who saw Dr. Cavuoto in 2024. The largest group is 65 to 74, with 59 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 38% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cavuoto's median patient age at 69, with 52% women.

In 2024, Dr. Cavuoto wrote 113 Medicare Part D claims for 52 patients. 82% of them were for generic drugs. CMS names the drug for 52 of them, across 4 drugs with 11 or more claims each, at $1,569 in total drug cost. In 2023, CMS named 51 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Cavuoto for performance year 2024, reported as part of a group. Dr. Cavuoto accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 161 papers to Dr. Cavuoto, published from 2007 to 2025. 2017 was the busiest year, with 17. The most frequent topics are Strabismus, Visual Acuity and Ophthalmology. Dr. Cavuoto has published most often in J AAPOS. Dr. Cavuoto's most frequent co-authors are Ta Chen Peter Chang, MD, Jayanth Srinivasan-Kasi Sridhar, MD and Hilda Capo, MD.

CMS Open Payments shows 9 general payments to Dr. Cavuoto from 7 drug and device companies from 2016 to 2023. Food and beverage make up the largest share, 100% of the total. Alcon Laboratories Inc paid the most, $250.

Dr. Cavuoto graduated from University of Miami, Miller School of Medicine in 2007.

Dr. Cavuoto is in network with 11 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.